News and views
August 2016 Br J Cardiol 2016;23:92
Correspondence: Sacubitril/valsartan: where should it sit in the heart failure pathway?
Dear Sirs,...
August 2016 Br J Cardiol 2016;23:96–7 Online First
Pulmonary hypertension news
In this report we review two major American meetings: the 36th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT), held in Washington DC, USA, from 27th–30th April 2016; and the Annual Meeting of the American Thoracic Society (ATS), held in San Francisco, USA, from 13th–18th May 2016....
July 2016 Br J Cardiol 2016;23:93 Online First
Highlights from international meetings: ACC, EAS and ADA
News highlights from the American College of Cardiology, European Atherosclerosis Society and American Diabetes Association....
July 2016 Br J Cardiol 2016;23:100 Online First
Cardiovascular applications:
apps – a beginner’s guide
Junior doctor Jonathan Bennett reviews cardiovascular apps and makes recommendations to fellow juniors of those he found most useful....
June 2016 Br J Cardiol 2016;23:51
New ESC heart failure guidelines
Updated European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and chronic heart failure have been published.1...
June 2016 Br J Cardiol 2016;23:51
NICE go-ahead for sacubitril/valsartan
The National Institute for Health and Care Excellence (NICE) has issued Technical Appraisal Guidance for sacubitril/valsartan (Entresto™, Novartis Pharmaceuticals). The drug has been approved for use within the NHS for the treatment of adults with symptomatic chronic heart failure with New York Heart Association class II to IV symptoms, a left ventricular ejection fraction of 35% or less, and who are also taking a stable dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers....
June 2016 Br J Cardiol 2016;23:56
Correspondence: Nicorandil, antithrombotic drugs, and non-variceal upper gastrointestinal bleeding
Dear Sirs,...
